secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001558370-25-006393
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences reports 20% Q1 revenue growth; reaffirms 2025 guidance $820-860M
--------------------------------------------------------------------------------

- Q1 net revenue $184.7M, +20% YoY; GAAP net income $45.6M ($0.78 diluted EPS).
- Non-GAAP adjusted net income $60.4M ($1.03 diluted EPS) vs $50.7M ($0.88) YoY.
- Reaffirms FY2025 revenue guidance $820-$860M; cash and investments >$600M.
- ZYN002 Phase 3 in Fragile X completed recruitment; topline data on track for Q3 2025.
- Pitolisant HD Phase 3 registrational trials in narcolepsy & IH on track to initiate Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/0001558370-25-006393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/hrmy-20250506x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer